Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 1/20 | 0.61 |
| ▸ | GSK3B | P49841 | 9/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MPI | P34949 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1368128 | 0.86 | GSK3B (0.59) | USP5GSK3BPTPN1POLBL3MBTL1 | |
| SCHEMBL30089581 | 0.83 | USP5 (0.85) | USP5POLBCYP2C9L3MBTL1RAB9A | |
| SCHEMBL269939 | 0.83 | USP5 (0.66) | USP5POLBCYP2C9L3MBTL1RAB9A | |
| SCHEMBL11744550 | 0.82 | GSK3B (0.55) | USP5GSK3BPTPN1RAB9ANPC1 | |
| SCHEMBL205280 | 0.82 | GSK3B (0.80) | GSK3BPTPN1RAB9ANPC1 | |
| SCHEMBL11290691 | 0.81 | USP5 (0.64) | USP5POLBCYP2C9L3MBTL1RAB9A | |
| SCHEMBL11796064 | 0.81 | USP5 (0.63) | USP5POLBCYP2C9L3MBTL1RAB9A | |
| SCHEMBL3404341 | 0.81 | USP5 (0.63) | USP5POLBCYP2C9L3MBTL1RAB9A | |
| SCHEMBL20221599 | 0.80 | ESR1 (0.55) | USP5GSK3BPTPN1CYP2C9 | |
| SCHEMBL17873488 | 0.79 | PTPN1 (0.61) | USP5GSK3BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154175-A1 | DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | disclosed |
| EP-3487856-B1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | BAYER AG (DE) | 2025-01-22 | — | — | EP | disclosed |
| US-12180227-B2 | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | BAYER AKTIENGESELLSCHAFT (DE) | 2024-12-31 | — | — | US | disclosed |
| CN-115554300-B | Diazabicyclo-substituted imidazopyrimidines and their use for the treatment of respiratory disorders | 拜耳股份公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240150338-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| EP-3638675-B1 | DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS | BAYER AG (DE) | 2024-04-17 | — | — | EP | disclosed |
| CN-117355300-A | Compounds and their use for the treatment of neurodegenerative, degenerative and metabolic diseases | 佛罗里达大学研究基金会公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-4277623-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2005103022-A1 | SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS | TRANSTECH PHARMA, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-6545009-B1 | Imidazole, oxazole and thiazole derivatives for regulation of peroxisome proliferator-activated receptor function; improving insulin resistance, treating impaired glucose tolerance and obesity, enhancing insulin sensitivity, etc. | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-04-08 | — | — | US | disclosed |
| CN-1314899-A | Retinoid-associated receptor regulators | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-09-26 | — | — | CN | disclosed |
| EP-1092711-A1 | RETINOID-ASSOCIATED RECEPTOR REGULATORS | Takeda Chemical Industries, Ltd. (JP) | 2001-04-18 | — | — | EP | disclosed |
| EP-0016277-B1 | 2-CARBONYL-3-HYDROXY-ALKENONITRILES, THEIR USE AS ANTI-ARTHRITIC AGENTS AND PROCESSES FOR THEIR PREPARATION | AMERICAN CYANAMID COMPANY (US) | 1981-12-02 | — | — | EP | disclosed |
| EP-0016277-A1 | 2-Carbonyl-3-hydroxy-alkenonitriles, their use as anti-arthritic agents and processes for their preparation | AMERICAN CYANAMID COMPANY (US) | 1980-10-01 | — | — | EP | disclosed |
| WO-1980000964-A1 | ANTI-INFLAMMATORY AGENTS INCLUDING 2-CARBONYL-3-HYDROXY-2-ALKENONITRILES | AMERICAN CYANAMID CO (US) | 1980-05-15 | — | — | WO | disclosed |
| US-4173650-A | ANTIARTHRITIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1979-11-06 | — | — | US | disclosed |
| US-4033978-A | Thiacycl[2.2.2]azine carboxylic acids | SYNTEX (U.S.A.) INC. (US) | 1977-07-05 | — | — | US | disclosed |
| US-3968121-A | 1,2-Diphenyl-4,5,6,7-tetrahydroindoles | STERLING DRUG INC. (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | USP5 2517/4885GSK3B 770/4885PTPN1 2829/4885 |
| US-12180227-B2 | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | HIF1AN, QDPR, DHPS | USP5 2846/4885GSK3B 4385/4885PTPN1 2067/4885 |
| US-20240150338-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | OAT, NLN, ABAT | USP5 3180/4885GSK3B 1033/4885PTPN1 4111/4885 |
| US-20250154175-A1 | DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS | HIF1AN, QDPR, HNMT | USP5 2348/4885GSK3B 4414/4885PTPN1 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.